JP2018536621A5 - - Google Patents

Download PDF

Info

Publication number
JP2018536621A5
JP2018536621A5 JP2018511684A JP2018511684A JP2018536621A5 JP 2018536621 A5 JP2018536621 A5 JP 2018536621A5 JP 2018511684 A JP2018511684 A JP 2018511684A JP 2018511684 A JP2018511684 A JP 2018511684A JP 2018536621 A5 JP2018536621 A5 JP 2018536621A5
Authority
JP
Japan
Prior art keywords
independently
xaa
cancer
macrocycle
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018511684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536621A (ja
JP6971970B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/050194 external-priority patent/WO2017040990A1/en
Publication of JP2018536621A publication Critical patent/JP2018536621A/ja
Publication of JP2018536621A5 publication Critical patent/JP2018536621A5/ja
Application granted granted Critical
Publication of JP6971970B2 publication Critical patent/JP6971970B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018511684A 2015-09-03 2016-09-02 ペプチド模倣大環状分子およびその使用 Expired - Fee Related JP6971970B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562214142P 2015-09-03 2015-09-03
US62/214,142 2015-09-03
US201662310254P 2016-03-18 2016-03-18
US62/310,254 2016-03-18
US201662344651P 2016-06-02 2016-06-02
US201662344791P 2016-06-02 2016-06-02
US62/344,791 2016-06-02
US62/344,651 2016-06-02
PCT/US2016/050194 WO2017040990A1 (en) 2015-09-03 2016-09-02 Peptidomimetic macrocycles and uses thereof

Publications (3)

Publication Number Publication Date
JP2018536621A JP2018536621A (ja) 2018-12-13
JP2018536621A5 true JP2018536621A5 (cg-RX-API-DMAC7.html) 2019-10-17
JP6971970B2 JP6971970B2 (ja) 2021-11-24

Family

ID=58188595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018511684A Expired - Fee Related JP6971970B2 (ja) 2015-09-03 2016-09-02 ペプチド模倣大環状分子およびその使用

Country Status (11)

Country Link
US (2) US20170114098A1 (cg-RX-API-DMAC7.html)
EP (1) EP3344275B8 (cg-RX-API-DMAC7.html)
JP (1) JP6971970B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180043835A (cg-RX-API-DMAC7.html)
CN (1) CN108348571B (cg-RX-API-DMAC7.html)
AU (1) AU2016315878A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018003985A2 (cg-RX-API-DMAC7.html)
CA (1) CA2996685A1 (cg-RX-API-DMAC7.html)
IL (1) IL257706A (cg-RX-API-DMAC7.html)
MX (1) MX2018002723A (cg-RX-API-DMAC7.html)
WO (1) WO2017040990A1 (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105061577A (zh) 2006-12-14 2015-11-18 爱勒让治疗公司 双巯基大环化系统
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CN104086641A (zh) 2007-02-23 2014-10-08 爱勒让治疗公司 三唑大环系统
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
US9175047B2 (en) 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AU2010298338A1 (en) 2009-09-22 2012-04-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2012021875A1 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with triazole linkers
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
CN112500466B (zh) 2012-02-15 2022-05-03 艾瑞朗医疗公司 拟肽大环化合物
CN104812384B (zh) 2012-11-01 2020-09-18 爱勒让治疗公司 二取代的氨基酸及其制备和使用方法
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
US10905739B2 (en) 2014-09-24 2021-02-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
WO2018074387A1 (ja) * 2016-10-17 2018-04-26 第一三共株式会社 Mdm2阻害剤とdnaメチルトランスフェラーゼ阻害剤との併用治療法
SG10202104386UA (en) 2016-10-28 2021-05-28 Icahn School Med Mount Sinai Compositions and methods for treating ezh2-mediated cancer
JP2020514252A (ja) 2016-12-08 2020-05-21 アイカーン スクール オブ メディスン アット マウント シナイ Cdk4/6媒介性がんを治療するための組成物および方法
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3621633A2 (en) * 2017-05-11 2020-03-18 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN110678483B (zh) 2017-06-01 2023-09-22 百时美施贵宝公司 用抗pd-1抗体治疗肿瘤的方法
WO2018218633A1 (en) * 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
CA3092677A1 (en) * 2018-03-06 2019-09-12 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (akt) degradation / disruption compounds and methods of use
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
CN112996518A (zh) 2018-06-21 2021-06-18 西奈山伊坎医学院 Wd40重复结构域蛋白5(wdr5)降解/破坏化合物和使用方法
US11091522B2 (en) * 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
BR112021002622A2 (pt) 2018-08-13 2021-05-11 Beijing Percans Oncology Co. Ltd. biomarcadores para terapia de câncer
KR20210052389A (ko) 2018-08-27 2021-05-10 리제너론 파마슈티칼스 인코포레이티드 다운스트림 정제에서의 라만 분광법의 사용
WO2020112868A1 (en) * 2018-11-30 2020-06-04 Aileron Therapeutics, Inc. Combination therapy of peptidomimetic macrocycles
TW202034918A (zh) * 2018-12-11 2020-10-01 美商卡托斯醫療公司 治療眼睛病況之方法及組合物
CN109731104A (zh) * 2018-12-29 2019-05-10 苏州明基医院有限公司 一种多肽-稀土材料递送系统及制备方法和应用
EP3938051A4 (en) * 2019-03-15 2022-12-07 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2020198734A1 (en) * 2019-03-28 2020-10-01 The Penn State Research Foundation Methods, compositions relating to treatment of cancer
EP3965824B1 (en) 2019-05-06 2025-01-08 Icahn School of Medicine at Mount Sinai Heterobifunctional compounds as degraders of hpk1
WO2021202961A1 (en) * 2020-04-02 2021-10-07 United States As Represented By Dept Of Veterans Affairs Methods of treating immunotherapy resistant metastatic melanoma
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
JP2023533447A (ja) 2020-06-24 2023-08-03 ピーエムブイ ファーマシューティカルズ, インコーポレイテッド がんを処置する併用療法
CN111825621A (zh) * 2020-07-22 2020-10-27 天津理工大学 一种奥拉帕尼与丙二酸的共晶及其制备方法
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
CN115137731B (zh) * 2022-05-19 2023-11-21 上海交通大学医学院附属新华医院 Flt3抑制剂及其药学上可接受的盐在制备治疗皮肤t细胞淋巴瘤药物中的应用
CN120077047A (zh) * 2022-10-21 2025-05-30 正大天晴药业集团股份有限公司 大环类化合物及其医药用途
GB202219576D0 (en) * 2022-12-22 2023-02-08 Univ Court Univ Of Glasgow Polypeptides
WO2025085740A1 (en) * 2023-10-20 2025-04-24 Alkermes, Inc. Compound for use in treating narcolepsy
WO2025096608A1 (en) * 2023-10-31 2025-05-08 The Board Of Trustees Of The Leland Stanford Junior University Egfr covalent inhibition with macrocycles

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5364851A (en) 1991-06-14 1994-11-15 International Synthecon, Llc Conformationally restricted biologically active peptides, methods for their production and uses thereof
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5824483A (en) 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
US6713280B1 (en) 1999-04-07 2004-03-30 Thomas Jefferson University Enhancement of peptide cellular uptake
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7202332B2 (en) 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US7932397B2 (en) 2006-11-22 2011-04-26 Massachusetts Institute Of Technology Olefin metathesis catalysts and related methods
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
CA2712503C (en) 2008-01-25 2017-04-18 Massachusetts Institute Of Technology Catalysts for metathesis reactions including enantioselective olefin metathesis, and related methods
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
CA2743177A1 (en) * 2008-11-24 2010-05-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
TW202442680A (zh) 2008-12-09 2024-11-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011097642A1 (en) 2010-02-08 2011-08-11 Trustees Of Boston College Efficient methods for z- or cis-selective cross-metathesis
WO2012021875A1 (en) * 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with triazole linkers
TWI835048B (zh) 2011-08-01 2024-03-11 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
CN112500466B (zh) * 2012-02-15 2022-05-03 艾瑞朗医疗公司 拟肽大环化合物
JP2015509503A (ja) * 2012-02-22 2015-03-30 ニューヨーク・ユニバーシティ 可逆的に架橋されたヘリックス状水素結合サロゲート大環状分子
RS60142B1 (sr) * 2013-12-05 2020-05-29 Hoffmann La Roche Novi kombinovani tretman za akutnu mijeloidnu leukemiju (aml)
US10905739B2 (en) * 2014-09-24 2021-02-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
EP3197478A4 (en) * 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
SG11201707750YA (en) * 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof

Similar Documents

Publication Publication Date Title
JP6971970B2 (ja) ペプチド模倣大環状分子およびその使用
JP2018536621A5 (cg-RX-API-DMAC7.html)
CN109414470A (zh) 用于拟肽大环化合物的伴随诊断工具
JP2018516844A (ja) ペプチド模倣大環状分子およびその使用
US11091522B2 (en) Peptidomimetic macrocycles and uses thereof
CN106999541A (zh) 拟肽大环化合物及其用途
JP2020519595A (ja) ペプチド模倣大環状分子およびその使用
CN114173878A (zh) 拟肽大环化合物及其用途
WO2020112868A1 (en) Combination therapy of peptidomimetic macrocycles
HK40043424A (en) Peptidomimetic macrocycles and uses thereof